Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum

Respiratory Research

Dave Singh²  Jørgen Vestbo¹  Matthew Catley³  Louise Healy³  George Booth²  Jonathan Plumb²  Jonathan Lemon²  Shruti Khurana⁴  Arjun K Ravi⁴ 

[1] Department of Cardiology and Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark;Manchester Academic Health Science Centre; University Hospital South Manchester NHS Foundation Trust; NIHR Respiratory and Allergy Clinical Research Facility, University of Manchester, Manchester, UK;UCB, Slough, Berkshire, UK;Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, University of Manchester, Manchester, UK

关键词: CCL3;    sIL-6R;    Interleukin-6;    Two-step sputum processing;    Sputum;    COPD;   

Others  :  1146150
DOI  :  10.1186/s12931-014-0103-4

 received in 2013-05-17, accepted in 2014-08-19,  发布年份 2014

【 摘 要 】

Background

COPD patients have increased numbers of macrophages and neutrophils in the lungs. Interleukin-6 (IL-6) trans-signaling via its soluble receptor sIL-6R, governs the influx of innate immune cells to inflammatory foci through regulation of the chemokine CCL3. We hypothesized that there would be enhanced levels of IL-6, sIL-6R and CCL3 in COPD sputum.

Methods

59 COPD patients, 15 HNS and 15 S underwent sputum induction and processing with phosphate buffered saline to obtain supernatants for IL-6, sIL-6R and CCL3 analysis. Cytoslides were produced for differential cell counting and immunocytochemistry (COPD; n?=?3) to determine cell type surface expression of the CCL3 receptors CCR5 and CCR1.

Results

COPD patients expressed higher levels (p?

Conclusion

Enhanced airway generation of sIL-6R may promote IL-6 trans-signaling in COPD. Associated upregulation of CCL3 may facilitate the recruitment of macrophages into the airways by ligation of CCR1 and CCR5.

【 授权许可】

   
2014 Ravi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2011.
• [2]Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniak RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653.
• [3]Noguera A, Batl S, Iglesias J, Busquets X, Macnee W, Agusti AGN: Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001, 56(6):432-437.
• [4]Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, Kobayashi DK, Ljem WG, Deslee G, Moore CH, Jacobs ME, Conradi SH, Gierada DS, Pierce RA, Betsujaku T, Senior RM: The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 2011, 183(7):876-884.
• [5]Stahl N, Boulton TG, Farrugella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD: Association and activation of Jak-Tyk Kinases by CNTF-LIF-OSM -IL-6 beta receptor components. Science 1994, 262(5143):92-95.
• [6]Heinrich P, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265(3):621-636.
• [7]Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55(2):114-120.
• [8]Soler N, Ewig S, Torres A, Filela X, Gonzalez J, Zaubet A: Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999, 14(5):1015-1022.
• [9]Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T: Molecular cloning and expression of an IL-6 signal transducer gp130. Cell 1990, 63(6):1149-1157.
• [10]Gómez MI, Sokol SH, Muir AB, Bastein J, Prince AS: Bacterial induction of TNF-? converting enzyme expression and IL-6 receptor ? shedding regulates airway inflammatory signaling. J Immunol 2005, 175(3):1930-1936.
• [11]Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S: Complex of soluble human IL-6 receptor/IL-6 upregulates expression of acute phase proteins. J Immunol 1992, 149(6):2021-2027.
• [12]Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Fuller GM, Topley N, Jones SA: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leucocyte recruitment seen during acute inflammation. Immunity 2001, 14(6):705-714.
• [13]Salentin R, Gemsa D, Sprenger H, Kaufmann A: Chemokine receptor expression and chemotactic responsiveness of human monocytes after influenza A virus infection. J Leuk Biol 2003, 74(2):252-259.
• [14]Fuke S, Betsuyaku T, Nasuhara Y, Morikawa T, Katoh H, Nishimura M: Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2004, 31(4):405-412.
• [15]Wang F, He B: CCR1 and CCR5 expression on inflammatory cells is related to cigarette smoking and chronic obstructive pulmonary disease. Chin Med J 2012, 125(23):4277-4282.
• [16]Fahey TJ III, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT, Sherry B: Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1992, 148(9):2764-2769.
• [17]Saito F, Tasaka S, Inoue KI, Miyamoto K, Nakano Y, Ogawa Y, Yamada W, Ishizaka A: Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2007, 38(5):566-571.
• [18]Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-completed measure of health status for chronic airflow limitation: the St George¿s respiratory questionnaire. Am J Respir Crit Care Med 1992, 145(6):1321-1327.
• [19]Fletcher CM, Elmes PC, Fairbairn AS, Wood CH: The significance of respiratory symptoms aid the diagnosis of chronic bronchitis in a working population. BMJ 1959, 2(5147):257-266.
• [20]Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N: Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34:648-654.
• [21]Definition and Classification of chronic bronchitis for clinical and epidemiological purposes Lancet 1965, 285(7389):775-779.
• [22]Wanger J, Clausen JL, Coates A, Pedersen O, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navjas D, Pellegrino R, Viegi G: Standardization of the measurement of lung volumes. Eur Respir J 2005, 26(3):511-522.
• [23]Macintyre N, Crapo R, Viegi G, Johnson D, van der Grinten C, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller M, Navajas D, Pederson O, Pellegrino R, Wanger J: Standardization of the single breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26(3):720-735.
• [24]ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 2002, 166(1):111-117.
• [25]Badafahel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, Mistry V, Reid C, Brightling CE: Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 2012, 83(1):36-44.
• [26]Vitale S, Schmid-Alliana A, Breuil V, Pomeranz M, Millet M-A, Rossi B, Scmid-Antomarchi H: Soluble Fractalkine prevents monocyte chemoattractant protein-1-induced monocyte migration via inhibition of stress-activated protein Kinase 2/p38 and matrix metalloproteinase activities. J Immunol 2004, 172(1):585-592.
• [27]Boyden S: The chemotactic effect of mixtures antibody and antigen on polymorphonuclear leucocytes. J Exp Med 1962, 115(3):453-466.
• [28]Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D: LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. Int Immunopharmacol 2012, 13(3):225-231.
• [29]Singh D, Edwards L, Tal-Singer R, Rennard S: Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Resp Res 2010, 11:77. BioMed Central Full Text
• [30]Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE: Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002, 57(7):590-595.
• [31]Pauwels NS, Bracke KR, Maes T, Pilette C, Joos GF, Bruselle GG: The role of interleukin 6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease. Exp Lung Res 2010, 36(8):469-483.
• [32]Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey B-G, O¿Connor TP, Crystal RG: Smoking dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of COPD. J Immunol 2009, 183(4):2867-2883.
• [33]Armstrong J, Sargent C, Singh D: Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol 2009, 158(1):74-83.
• [34]Han MK, Agusti A, Calvery P, Celli B, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard S, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ: Chronic obstructive pulmonary disease phenotypes - the future of COPD. Am J Respir Crit Care Med 2010, 182(5):598-604.
• [35]Donaldson GC, Seemungal TAR, Patel IS, Bhowmick A, Wilkinson TMA, Hurst JR, MacCallum PK, Wedzicha JA: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005, 128(4):1995-2004.
• [36]Chen Y, Thai P, Zhao Y-H, Ho Y-S, de Souza MM, Wu R: Stimulation of airway mucin gene expression by IL-17 through IL-6 Paracrine/Autocrine loop. J Biol Chem 2003, 278(19):17036-17043.
• [37]Snoeck-Stroband JB, Lapperre TS, Gosman MME, Boezen HM, Times W, ten Hacken NHT, Sont JK, Sterk PJ: Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008, 31(1):70-77.
• [38]de Oca MM, Halbert RJ, Lopez MV, Perez-Padilla R, Tálamo C, Muiño A, Jardim JRB, Valdivia G, Pertuzé J, Menezes AMB: The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012, 40(1):28-36.
• [39]Mons? E, Rosell A, Bonet G, Manterola J, Cardona PJ, Ruiz J, Morera J: Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999, 13(2):338-342.
• [40]Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002, 57(9):759-764.
• [41]Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW, Hoffmann F, Hector A, Eber E, Marcos V, Bittmann I, Eickelberg O, Griese M, Roos D: Infiltrated neutrophils acquire novel Chemokine receptor expression and Chemokine responsiveness in chronic inflammatory lung diseases. J Immunol 2008, 181(11):8053-8067.
• [42]Houssiau FA, Devogelaer JP, Van Damme J, Nagant de Deux-chaisnes C, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988, 31(6):784-788.
• [43]Atreya R, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehir HA, Autscbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF: Blockade of interleukin-6 trans-signalling suppresses T cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn¿s disease and experimental colitis in vivo. Nat Med 2000, 6(5):583-588.
• [44]Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C: STAT 3 regulates cytokine mediated generation of inflammatory helper T cells. J Biol Chem 2007, 282(13):9358-9363.